Comment on ​Trial suggests Alnylam's cholesterol-lowering drug may last longer than Amgen's

​Trial suggests Alnylam's cholesterol-lowering drug may last longer than Amgen's

Amgen’s newest cholesterol-lowering drug has only been approved for three days, with plans to launch this coming week. But already, Alnylam Pharmaceuticals in Cambridge is coming out with early-stage trial data suggesting it has a drug that can achieve similar results with far less frequent injections. Cambridge-based Alnylam (Nasdaq: ALNY) presented results of an early-stage trial today at a conference in London for a drug that lowers levels of a protein made in the liver called PCSK9, which…

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News